Finoriq research workspace
Bicara Therapeutics Inc. (BCAX) Historical Metrics
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of. Review BCAX valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
- Company
- Bicara Therapeutics Inc. (BCAX)
- Ticker
- BCAX
- Market Cap
- $1.8B
- Latest Price
- $27.27
- Industry
- Biotech & Pharma
Bicara Therapeutics Inc. (BCAX) Current Valuation Metrics
Static valuation preview for Bicara Therapeutics Inc. (BCAX). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -7.3% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -5.6% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 4.71x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.